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Introduction 
Acute promyelocytic leukemia (APL), characterized by 
the balanced translocation t(15;17)(q22;q12) resulting in the 
fusion transcript PML-RARA, is a rare entity of acute 
myeloid leukemia, accounting for roughly 5-8% of cases of 
acute myeloid leukemia.1 With the introduction of all-trans 
retinoic acid (ATRA) and arsenic trioxide (ATO), the prog-
nosis of APL has been transformed and this is now one of 
the most curable malignant diseases.  
Published data from a large multicenter phase III random-
ized trial (APL0406) on a direct comparison of ATO/ATRA 
versus ATRA in combination with idarubicin (AIDA) or 
mitoxantrone in adult patients with de novo, low-/interme-
diate-risk APL showed very promising results in favor of 
ATO/ATRA, with a 2-year event-free survival rate of 97% 
versus 86% (P=0.02).2 Within this trial, the early mortality 
rate as well as hematologic toxicities were significantly 
lower in patients treated with ATO/ATRA than in those 
treated with AIDA. In particular, the cumulative incidence 
of relapse after 50 months was only 1.9% after ATO/ATRA 
as compared to 13.9% after chemotherapy and ATRA.3 
Moreover, none of the patients treated with ATO/ATRA 
developed a therapy-related myeloid neoplasm as com-
pared to two patients in the chemotherapy/ATRA arm.3 
Another Medical Research Council publication supported 
these results, with a 4-year event-free survival rate of 91% 
after ATO/ATRA as compared to 70% after chemotherapy 
and ATRA (P=0.002).4 The ATO/ATRA regimen was, how-
ever, associated with a higher frequency of grade 3 or 4 
hepatic toxicity (44% vs. 3%; P<0.001). In all cases, toxic 
effects resolved with temporary discontinuation of ATO 
and/or ATRA3 and the chemotherapy-free regimen with 
ATO/ATRA has become standard first-line therapy in low-
/intermediate-risk de novo APL. However, apart from 
reports of the randomized Italian-German APL04062,3 and 
the AML17 trials,4 data on outcomes after up-front treat-
ment with ATO/ATRA in the real-world setting are scarce.  
Previously published data from registries and population-
based studies indicated that outcomes of patients with APL 
were inferior to those reported in clinical trials, mainly due 
to higher early death rates.5-8 However, none of these stud-
ies included results after treatment with ATO/ATRA. 
Recently published results from the randomized Italian-
German APL0406 trial suggest, albeit within the context of 
highly selected patients and closely monitored therapy, that 
treatment with ATO/ATRA can reduce early deaths and 
improve long-term outcomes.2,3 Whether or not these 
results can be replicated in population-based settings is cur-
rently unclear. 
The objectives of our study were to characterize a large 
series of APL patients included in the prospective 
NAPOLEON registry and evaluate their outcome after up-




Patients and treatment 
Data on 167 APL patients, reported within the NAPOLEON 
registry (ClinicalTrials.gov Identifier: NCT02192619) between 
2013 and 2019 within two large European study groups (APL 
French group, n=89; Study Alliance Leukemia, n=78) were collect-
ed. This real-life registry included data on patients’ demographics, 
treatment, response, severe adverse events and follow-up. There 
were no criteria for exclusion of APL patients from this registry. 
However, for the current analysis the inclusion criterion was treat-
ment with ATO/ATRA and exclusion criteria were age below 18 
years (n=6), high-risk APL (white blood cell [WBC] count 
>10x109/L, at diagnosis, n=4) and lack of data on WBC count 
(n=3). The final study cohort consisted of 154 patients. Ideally, 
patients were included within the same (n=45) or following (n=32) 
day of APL diagnosis. Additionally 46 patients were included 
within the first 8 days after diagnosis (overall n=123; 80%), when 
the risk of early death is highest.8 Outcome was calculated using 
the date of initial diagnosis. None of the patients was treated 
within a clinical trial. 
The diagnosis of APL was based on genetic analysis as well as 
on French-American-British Cooperative Group criteria,9 and, 
after 2003, on revised International Working Group criteria.10 
Chromosome banding analysis was performed using standard 
techniques, and karyotypes were described according to the 
International System for Human Cytogenetic Nomenclature.11 
The diagnosis was confirmed by either reverse-transcriptase poly-
merase chain reaction (RT-PCR) or fluorescence in-situ hybridiza-
tion (FISH) detection by standard methods. FLT3 mutation screen-
ing for internal tandem duplications (ITD) and point mutations 
within the tyrosine kinase domain was carried out as previously 
The aim of this study was to characterize a large series of 154 patients with acute promyelocytic leukemia (median age, 53 years; range, 18-90 years) and evaluate real-life outcome after up-front treatment with arsenic trioxide and all-trans retinoic acid. All patients were included in the prospec-
tive NAPOLEON registry (NCT02192619) between 2013 and 2019. The acute promyelocytic leukemia was 
de novo in 91% (n=140) and therapy-related in 9% (n=14); 13% (n=20) of the patients were older than 70 
years. At diagnosis bleeding/hemorrhage was present in 38% and thrombosis in 3%. Complete remission 
was achieved in 152 patients (99%), whereas two patients (1%) experienced induction death within 18 
days after starting therapy. With a median follow-up of 1.99 years (95% confidence interval: 1.61-2.30 
years) 1-year and 2-year overall survival rates were 97% (95% confidence interval: 94-100%) and 95% 
(95% confidence interval: 91-99%), respectively. Age above 70 years was associated with a significantly 
shorter overall survival (P<0.001) compared to that of younger patients. So far no relapses have been 
observed. Six patients (4%) died in complete remission at a median of 0.95 years after diagnosis (range, 
0.18-2.38 years). Our data confirm the efficiency and durability of arsenic trioxide and all-trans retinoic acid 
therapy in the primary management of adults with low-/intermediate-risk acute promyelocytic leukemia in 
the real-life setting, irrespective of age. 
ABSTRACT
described.12,13 Data collection and analysis were approved by the 
local Institutional Review Boards. 
Treatment 
All patients were treated with ATO/ATRA as induction thera-
py and with up to four consolidation cycles of ATO/ATRA.2 
Eight patients additionally received 12 mg/m2 idarubicin (for up 
to 4 days) and two patients received 100 mg/m2 cytarabine for 
up to 2 days during induction with ATO/ATRA because of WBC 
counts rising above 10x109/L. One elderly patient (age, 72 years) 
was initially treated with decitabine (38 mg/day) for 5 days and 
was then switched to two cycles of ATO/ATRA after genetic 
analysis revealed t(15;17). Response was assessed according to 
Cheson et al.10 
Statistical analyses 
Survival endpoints including overall survival and cumulative 
incidence of death in complete remission were defined according 
to the revised recommendations of the International Working 
Group.10 Induction death was defined as death occurring at any 
time during induction therapy before the achievement of com-
plete remission. Comparisons of patients’ characteristics were per-
formed with the Kruskal-Wallis rank sum test for continuous vari-
ables and Fisher exact test for categorical variables. The median 
follow-up time was computed using the reverse Kaplan-Meier 
estimate.14 The Kaplan-Meier method was used to estimate the 
distribution of overall survival.15 Confidence interval (CI) estimates 
for survival curves were based on the cumulative hazard function 
using the Greenwood formula for variance estimation. Log-rank 
tests were employed to compare survival curves between groups. 
The cumulative incidence of death in complete remission and the 
standard error were computed using the method described by 
Gray16 and included only patients attaining complete remission. 
All statistical analyses were performed with the statistical soft-
ware environment R, version 3.3.1, using the R packages, and sur-




In total, data on 154 low-/intermediate-risk APL patients, 
reported within the NAPOLEON registry between 2013 
and 2019 within two large European study groups were 
included. The median age of these patients was 53 years 
(range, 18-90 years); 13% (n=20) were older than 70 years. 
APL was de novo in 91% (n=140) and therapy-related in 9% 
(n=14). Primary malignancies included solid cancers in 12 
patients (breast cancer, n=5; female genital tract, n=2; 
prostate cancer, lung cancer, colon cancer, intraabdominal 
liposarcoma, and epidermoid cancer, n=1 each) and lym-
phoma in two patients. All patients received chemotherapy 
and/or radiation as treatment for the prior malignancy/neo-
plasm and were in remission at the time of APL diagnosis. 
The median latency period between diagnosis of the pri-
mary malignancy/neoplasm and the occurrence of therapy-
related APL was 2.80 years (range, 1.68-7.70 years). 
Information on extramedullary disease was available for 
131 patients and was present in two (1.5%) patients (skin 
manifestation, hepatosplenomegaly; n=1 each). 
Comorbidities were present in 48 (58%) of 83 patients and 
included arterial hypertension (n=25), pulmonary disease 
(n=12; mild, n=5, moderate/severe, n=7), gastro-intestinal 
disease (n=9), renal disease (n=8; mild, n=4, 
moderate/severe, n=4), diabetes (n=8), psychiatric distur-
bance (n=8), cardiac/arrhythmias (n=6), rheumatologic dis-
order (n=5), hepatic disease (n=3, mild, n=1, 
moderate/severe, n=2), cerebrovascular disease (n=3), and 
immunosuppression due to human immune-deficiency 
virus infection (n=2). 
In all patients APL was confirmed by cytogenetics and/or 
FISH/RT-PCR. Information on cytogenetics was available 
for 132 (86%) patients. In seven (5%) patients t(15;17) could 
only be detected by FISH and/or RT-PCR, while cytogenet-
ics showed a normal karyotype. In 82 (66%) of the remain-
ing 125 patients, the balanced t(15;17) translocation was the 
sole abnormality, whereas in 43 (34%) patients, the translo-
cation was accompanied by additional cytogenetic abnor-
malities, most frequently t(15;17) within a complex kary-
otype, i.e., ≥2 cytogenetic abnormalities in addition to 
t(15;17) (n=16) or trisomy 8 (n=7).  
Regarding FLT3-ITD mutational status, information was 
available for 51 (33%) of the 154 patients. Of those, eight 
(16%) patients were FLT3-ITD-positive. Information on the 
PML-RARA transcript isoform (breakpoint cluster region, 
BCR) was available for 104 (67%) patients and 50 had the 
short isoform (BCR3). The patients’ baseline characteristics 
are shown in Table 1.  
Response to induction therapy  
Overall, 152 patients (99%) achieved complete remission, 
whereas two patients (1%) experienced induction death 
within 18 days after starting therapy due to acute respirato-
ry failure with bilateral pneumonia in one case and 
ischemic cardiomyopathy in the other. Both patients had de 
novo APL, Eastern Cooperative Oncology Group perform-
ance status ≤2 and no signs of hemorrhage or thrombosis at 
initial presentation. They were 64 and 75 years old. 
Cytogenetics in both cases revealed t(15;17) as the sole 
abnormality; no concurrent FLT3-ITD was present.  
None of the patients was refractory to treatment. In uni-
variable analysis age above 70 years had no impact on 
response to induction therapy (P=0.24).  
Survival analysis  
The median follow-up for survival was 2 years (95% CI: 
1.61-2.30 years). Overall, the estimated 1-year and 2-year 
overall survival rates were 97% (95% CI: 94-100%) and 
95% (95% CI: 91-99%), respectively (Figure 1). The overall 
survival rate was significantly lower in elderly patients (>70 
years) than in younger patients (P<0.001) (Figure 2). 
None of the patients relapsed after ATO/ATRA treat-
ment, thus overall survival and event-free survival were 
identical. Six (4%) patients died in remission at a median of 
0.95 years after diagnosis (range, 0.18-2.38 years). Of these 
patients, three were below 70 years old. Causes of death 
were sepsis (n=2), bleeding/hemorrhage (n=1), pulmonary 
edema due to tachycardic atrial fibrillation (n=1), progress 
of an underlying intra-abdominal liposarcoma (n=1) as well 
as hepato-renal syndrome (n=1). The cumulative incidence 
of death in complete remission was significantly higher in 
older patients  than in younger patients (P=0.001) (Figure 3). 
So far, none of the patients has developed a secondary neo-
plasm after treatment with ATO/ATRA.  
Toxicity 
A total of 118 serious adverse events were reported in 60 
patients, mainly infections (n=31), hepatobiliary events 
(n=21), neurotoxicity/neuropathy (n=9, including headache 
in 2 patients), and cardiac events (n=6, including QTc pro-
longation in 2 patients). Serious adverse events classified as 
S. Kayser et al.
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related to differentiation syndrome were reported in seven 
patients. As prophylaxis for the differentiation syndrome 
prednisone at a dose of 0.5 mg/kg of body weight per day 
was administered from day 1 until the end of induction 
therapy.2 Toxicities are listed in Table 2. Due to the adverse 
event, ATRA was withdrawn in five patients, and restarted 
in four, requiring a dose reduction to 50% in one of the 
patients. ATO was withdrawn in two patients, and restart-
ed in one; additionally, three patients had dose reductions. 
Most of the patients recovered from the serious adverse 
events (n=52), although eight patients died. Of the eight 
fatal serious adverse events, two occurred during induction 
within 18 days (acute respiratory failure with bilateral 
pneumonia, n=1; and ischemic cardiomyopathy, n=1) and 
six occurred in complete remission (infection/sepsis, n=2, 
bleeding/hemorrhage, n=1; pulmonary edema due to 
tachycardic atrial fibrillation n=1; progress of an underlying 
intraabdominal liposarcoma n=1, and hepato-renal syn-




This is the largest real-life data analysis of first-line 
ATO/ATRA treatment in a prospective registry in low-
/intermediate-risk APL patients. It confirms a very high 
response rate as well as excellent overall survival with this 
new standard of care.2,3 Our data confirm that results can be 
replicated in a clinical registry, even within the context of 
non-selected patients and less closely monitored therapy 
than in the pivotal study. Indeed, on the basis of our registry 
data, the outcome of patients was identical to that reported 
after treatment with ATO/ATRA within the APL0406 
trial.2,3 In contrast, the outcome of APL patients from previ-
ously published registries or population-based studies was 
inferior to that reported in clinical trials, mainly because of 
higher early death rates.5-8 However, these registries and 
population-based studies included results before treatment 
with ATO/ATRA had been approved by regulatory author-
ities.5-8  
In our cohort the rate of induction death was extremely 
low, which might be in part attributable to improved sup-
portive care and awareness of APL as a medical emer-
gency,18 but also to early treatment with ATO/ATRA itself. 
Thus, effective strategies due to standardized guidelines 
along with consultative support and sharing of expertise 
seem to be well-taken and overcome induction mortality.19 
Only two patients died during induction, in one case due to 
ischemic cardiomyopathy and in the other acute respiratory 
failure as a result of bilateral pneumonia. More impressive-
ly, none of the patients experienced induction death due to 
bleeding/hemorrhage or infections, which is in sharp con-
trast to previously published data on AIDA-based treat-
ment.20,21 Nevertheless, we cannot rule out a potential selec-
tion bias since patients may also die before diagnosis. High-
risk APL (WBC count >10x109/L) at diagnosis is a known 
risk-factor for a bleeding diathesis.22 The European random-
ized intergroup study “APOLLO” is currently investigating 
idarubicin 12 mg/m2 on days 1 and 3 in addition to oral 
ATRA 45 mg/m2 twice daily on days 1-28 and ATO 0.15 
mg/kg/day intravenously on days 5-28 followed by four 
cycles of ATO/ATRA consolidation therapy as compared to 
the standard chemotherapy/ATRA approach 
(ClinicalTrails.gov identifier: NCT02688140). 
The induction death rate in our analysis even compares 
favorably with the recently published data from the 
Swedish Acute Leukemia Registry, which recorded an early 
death rate of 15% in newly diagnosed, low-/intermediate-
risk APL (n=65) for the observation period 2009-2013.8 
Thus, early treatment with ATO/ATRA seems to tackle the 
threat of induction death, again confirming recently pub-
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Table 1. Characteristics of the 154 patients with acute promyelocytic 
leukemia at diagnosis.   
                                                          N=154                           % 
 Gender: female                                             75                                    49 
 Type of APL 
      De novo                                                     140                                   91 
      Therapy-related                                       14                                     9 
 ECOG performance status 
      0                                                                   42                                    27 
      1                                                                   84                                    55 
      2                                                                    9                                      6 
      3                                                                    3                                      2 
      4                                                                    3                                      2 
      Missing                                                      13                                     8 
 Bleeding/hemorrhage 
      Overall                                                       59                                    38 
      Skin                                                             32                                    21 
      CNS bleeding                                             3                                      2 
      Pulmonary                                                  1                                      1 
      Missing                                                        1                                      1 
 Thrombosis                                                    5                                      3 
 Missing                                                             5                                      3 
 BCR1/2                                                             54                                    35 
 BCR3                                                               50                                    32 
 Missing                                                            50                                    32 
 Cytogenetics 
      Normal                                                       7                                      5 
      Sole abnormality                                      82                                    53 
      Additional abnormalities                       43                                    28 
         - Complex*                                         16/43                                  37 
         - Trisomy 8                                            7/43                                   16 
      Missing                                                      22                                    14 
 FLT3-ITD positive                                        8/51                                   16 
 Missing                                                           103                                   67 
 FAB subtype 
      M3                                                              138                                   90 
      M3v                                                               7                                      5 
      Missing                                                        9                                      6 
                                                           Value                        Range 
 Median ITD allelic ratio                            0.113                             0.01-63 
 Median age, years                                         53                                  18-90 
 N. >70 years                                                   20                                   13% 
 Median WBC, x 109/L                                    1.2                                 0.2-10 
 Median platelets x 109/L                              41                                  2-210 
 Median hemoglobin, g/dL                           10                                3.5-14.8 
 Missing                                                             1 
 Median BM blasts,** %                              65                                   0-95 
 Missing                                                            23 
 Median creatinine, mg/dL                         0.88                             0.49-8.14 
 Missing                                                             8 
APL; acute promyelocytic leukemia; ECOG: Eastern Cooperative Oncology Group; 
CNS: central nervous system; BCR, breakpoint cluster region; ITD: internal tandem 
duplication; FAB: French American British; WBC: white blood cell counts; BM: bone 
marrow. Percentages may not add to 100 because of rounding. *Two or more cyto-
genetic abnormalities in addition to t(15;17); **Blast cells included malignant 
promyelocytes. Percentages may not sum up to 100 due to rounding.
lished results on ATO/ATRA from the randomized Italian-
German APL0406 trial.2,3 However, part of the difference 
may be explained by the fact that the Swedish report con-
tained data from a population-based registry, whereas for 
our data, selective reporting cannot be ruled out. The under-
lying patho-mechanism by which ATO in combination 
with ATRA exerts this effect remains elusive. The transcrip-
tion factor PML-RARA behaves as an altered retinoic acid 
receptor with the ability to transmit oncogenic signals lead-
ing to accumulation of undifferentiated promyelocytes.23 
ATRA induces disease remission in APL patients by trigger-
ing terminal differentiation of leukemic promyelocytes. In 
addition, ATO has been shown to contribute to degrada-
tion of the PML-RARA oncoprotein through binding the 
PML moiety.23,24  
Regarding post-remission outcome, results of the ran-
domized North American Leukemia Intergroup Study 
C9710 on 481 APL patients evaluating ATO in first-line 
therapy during consolidation demonstrated that ATO fur-
ther reduced the risk of relapse and improved survival as 
compared to consolidation with daunorubicin/cytarabine.25 
In addition, the randomized phase-III AML17 trial of the 
UK National Cancer Research Institute Acute Myeloid 
Leukaemia Working Group showed significantly better 
event-free survival and relapse-free survival after 
ATO/ATRA than after the AIDA-based regimen.4 In line 
with previously published results2,3 overall survival was 
excellent in our cohort. In addition, the death rate in remis-
sion was also very low at 4%, again arguing for the safety 
and efficacy of ATO/ATRA as consolidation treatment. In 
comparison, relatively high rates of deaths in remission, 
mainly due to infectious complications, were reported with 
AIDA treatment.20,21  
Data on measurable residual disease was available for 
only a subgroup of patients before or after first consolida-
tion (25%). Nevertheless, since no relapse was observed, 
our data as well as the currently up-dated APL recommen-
dations of the European LeukemiaNet suggest that post-
consolidation measurable residual disease monitoring can 
be avoided in this setting and performed only in high-risk 
patients (WBC count >10×109/L) in routine clinical prac-
tice.18 
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Figure 1. Kaplan Meier plot of overall survival. Green and red curves indicate 
upper and lower 95% confidence intervals, respectively. 
Figure 3. Cumulative incidence of death according to age.
Figure 2. Kaplan Meier plot of overall survival according to age. Red curve indi-
cates age >70 years, black curve indicates age ≤70 years.  
Table 2. Reported serious adverse events. 
 Serious adverse events                     N=118                           % 
 Infection/sepsis                                            31                                    26 
 Hepatobiliary                                                 21                                    18 
 Neurotoxicity/neuropathy                            9                                      8 
 Differentiation syndrome                           7                                      6 
 Cardiac, total                                                  6                                      5 
      QTc prolongation                                     2 
      Pericarditis                                                1 
      Hypertension                                             1 
      Cardiac decompensation                        1 
      Ischemic cardiomyopathy                      1 
 Hematologic toxicity                                     5                                      4 
 Hemorrhage/bleeding                                  4                                      3 
 Thromboembolic complications                4                                      3 
 Other                                                               31                                    26 
Percentages may not sum up to 100 due to rounding.
Another positive finding is that none of the patients 
developed a secondary malignancy after ATO/ATRA, com-
pared to 2% after chemotherapy,26 representing a major 
improvement in APL treatment, although we acknowledge 
that the median follow-up time of our cohort is relatively 
short. However, the reported latency period between the 
diagnosis of APL and the development of a secondary 
malignancy of 6.6 months (range, 3.8-7.6 months) as report-
ed by Pagano et al. on behalf of the Gruppo Italiano 
Malattie Ematologiche dell'Adulto argues strongly for a true 
lower incidence after ATO/ATRA.27 The low relapse rate 
after ATO-based therapy in our cohort is in line with other 
reports.2,3,28 
Confirming our previously published data,29 ATO/ATRA 
was also effective in elderly patients, although age above 70 
years was associated with a shorter overall survival and 
higher cumulative incidence of death in complete remission 
in comparison with those outcomes in younger patients. 
Nonetheless, ATO/ATRA should not be withheld in older 
patients, particularly in light of its high efficacy and safety 
profile. 
The toxicity profiles were comparable to those previ-
ously published.2,3 The serious adverse events were main-
ly infections and elevation of liver enzymes. Hepatic tox-
icity has frequently been reported in studies of ATO, par-
ticularly in terms of increased liver enzymes.2,3,30 Although 
frequent, this complication is usually reversible and suc-
cessfully managed with temporary discontinuation of 
ATO.31 Neurological toxicity, mainly consisting of periph-
eral neuropathy, has also been reported.2,3,30 This side 
effect is usually managed with temporary drug discontin-
uation.31 QTc prolongation is another common side effect 
of ATO. It can lead to torsade-de-pointes-type ventricular 
arrhythmia, which is potentially fatal.2 However, the 
reported rate of QTc prolongation was lower than previ-
ously published,2-4 as was the rate of differentiation syn-
drome,2-4 although the data might be biased due to incom-
plete reporting. In our series, most of the patients recov-
ered from their serious adverse events, although the out-
come was fatal in eight cases. 
An unresolved issue is whether or not central nervous sys-
tem prophylaxis is needed in APL. Pharmacodynamic stud-
ies of plasma levels indicated that about one third of ATO 
crosses the blood–brain barrier, which suggests that a suffi-
cient amount of the drug is available on site to prevent dis-
ease recurrence.32 In addition, no ATO accumulation or 
delayed toxicity was observed in patients followed up for 
over 10 years.34,35 However, none of our patients was report-
ed to have central nervous system involvement at diagnosis.  
Regarding biological characteristics, additional cytoge-
netic abnormalities were present in 28% of the patients, 
most frequently t(15;17) within a complex karyotype or 
trisomy 8, which is in line with published data.35,36 
Although data were limited to a small number of patients, 
FLT3-ITD mutations were less frequent in our cohort 
than in published data (31%).37 To date, there are still con-
flicting data regarding the impact of additional chromoso-
mal or genetic abnormalities on outcome in APL 
patients.38-46 In our large cohort, neither the presence of 
additional cytogenetic abnormalities nor FLT3-ITD had 
an impact on overall survival, suggesting that ATO/ATRA 
may abrogate the negative prognostic impact of FLT3-
ITD.46 The latter issue, however, should be interpreted 
with caution given the limited availability of data on FLT3 
mutational status in our cohort. 
In conclusion, our real-life data showed excellent and sus-
tained response rates after ATO/ATRA for first-line treat-
ment of APL, confirming published results from the AP0406 
trial.2,3 Compared to reported historical data, the induction 
death rate was extremely low despite a high bleeding/hem-
orrhage rate at diagnosis, probably attributable to improved 
supportive care and awareness of APL as a medical emer-
gency, but also to early treatment with ATO/ATRA itself. 
Our results confirm the efficiency and sustainability of 
ATO/ATRA in the primary management of adults with 
low-/intermediate-risk APL in the real-life setting, irrespec-
tive of their age. 
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